Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Prospective, Multicentric, Open Label, Phase II Study Aiming to Evaluate the Efficacity and Safety of EVEROLIMUS as Neo-adjuvant Therapy in Patients With Primary or Relapsed Chondrosarcomas

NCT02008019 is registered in ClinicalTrials.gov with Centre Leon Berard as lead sponsor.

NCT NCT02008019
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02008019 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Prospective, Multicentric, Open Label, Phase II Study Aiming to Evaluate the Efficacity and Safety of EVEROLIMUS as Neo-adjuvant Therapy in Patients With Primary or Relapsed Chondrosarcomas
Lead sponsor
Centre Leon Berard
Phase
Phase 2
Overall status
Suspended
Start date
August 14, 2014
Completion date
August 31, 2019
Enrollment
57 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

chondrosarcoma